1. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use 
Michael Copland, MD, Paul Komenda, MD, Eric D. Weinhandl, PhD, MS, Peter A. McCullough, MD, MPH, Jose A. Morfin, MD 
American Journal of Kidney Diseases 
Volume 68, Issue 5, Pages S24-S32 (November 2016)
DOI: /j.ajkd
Copyright © 2016 National Kidney Foundation, Inc. Terms and Conditions

2. Figure 1
Distribution of 3-month mean serum phosphorus levels in the Dialysis Outcomes and Practice Patterns Study Practice Monitor, December
American Journal of Kidney Diseases  , S24-S32DOI: ( /j.ajkd )
Copyright © 2016 National Kidney Foundation, Inc. Terms and Conditions

3. Figure 2
Medicare Part D gross costs per patient-year for phosphate binders, by dialysis provider organization or class, Abbreviations: DCI, Dialysis Clinic, Inc; FDF, free-standing dialysis facility; HDF, hospital-based dialysis facility; SDO, small dialysis organization.
American Journal of Kidney Diseases  , S24-S32DOI: ( /j.ajkd )
Copyright © 2016 National Kidney Foundation, Inc. Terms and Conditions

4. Figure 3
Effects of intensive versus conventional hemodialysis on serum phosphorus levels in the Frequent Hemodialysis Network (FHN) Daily Trial,35 FHN Nocturnal Trial,35 and Canadian trial of nocturnal hemodialysis.36 Estimated treatment effects (solid dots) and associated 95% confidence intervals (solid lines) are displayed at the bottom.
American Journal of Kidney Diseases  , S24-S32DOI: ( /j.ajkd )
Copyright © 2016 National Kidney Foundation, Inc. Terms and Conditions

5. Figure 4
Mean equivalent phosphorus binding dose for intensive versus conventional hemodialysis in the Frequent Hemodialysis Network (FHN) Daily Trial.35 Dashed bars span 1 standard deviation above and below the mean.
American Journal of Kidney Diseases  , S24-S32DOI: ( /j.ajkd )
Copyright © 2016 National Kidney Foundation, Inc. Terms and Conditions

6. Figure 5
Distribution of equivalent phosphorus binding dose (EQBD) for intensive versus conventional hemodialysis in the Frequent Hemodialysis Network (FHN) Nocturnal Trial.35
American Journal of Kidney Diseases  , S24-S32DOI: ( /j.ajkd )
Copyright © 2016 National Kidney Foundation, Inc. Terms and Conditions